Elligo Health Research, a healthcare-enabling research organization, is launching their System of Accelerated Research (SOAR) model for decentralized (DCTs) and hybrid trial models with fully remote monitoring capabilities.
Elligo’s SOAR model expands patient access to reach diverse patient populations that typically don’t have access to clinical research as a care option. The solution drives efficiency by enabling direct data from source to submission and full remote site access, empowering patients, physicians, and sponsors to conduct more trials efficiently and faster in traditional and decentralized models.
“We are extremely excited to launch our tech-enabled solution created to keep the patient and the physician at the heart of its design, while providing sponsors transparency,” said John Potthoff, PhD, CEO of Elligo. “Our goal has always been to provide all patients with access to research as a healthcare option, which is important now more than ever as we navigate the future of clinical research.”
SOAR aims to adhere to regulations and improves data quality while decreasing resource requirements and costs associated with clinical research. Paired with technology-enabled services and personnel, this model accelerates research without compromising quality and integrity. This provides a pathway to either use traditional research sites, DCTs, or hybrid trials, seamlessly moving between options without causing disruption for any stakeholders. This modernizes clinical research for a new paradigm in a new age of clinical research.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
Vabysmo Shows Significant Vision Improvement for Diabetic Macular Edema in Underrepresented Patients
October 22nd 2024Phase IV ELEVATUM trial results show that one year of treatment with Vabysmo significantly improved vision in underrepresented racial and ethnic groups with diabetic macular edema, supporting the drug's efficacy and safety across diverse populations.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Clesrovimab Shows Significant Reduction in RSV Infections, Hospitalizations in Infants
October 18th 2024Merck's investigational monoclonal antibody, clesrovimab, shows significant efficacy in reducing respiratory syncytial virus-related infections and hospitalizations in infants, with a favorable safety profile.